Drug intelligence / Profile preview

Vernex

Development stage: Preclinical
Lead developer: Regenics
Administration: Topical

Overview

Vernex (REG320) is a medical device developed by Regenics for the treatment of wounds, including burns and chronic wounds. It is formulated as a hydrogel wound spray incorporating HTX, a proprietary bioactive extract derived from salmon roe. The product is designed to facilitate wound healing by providing a moist environment and potentially leveraging the regenerative properties of the salmon roe-derived components. As of the current pipeline information, Vernex is in the preclinical stage of development.

Brand names: Vernex

Beyond the preview

Go deeper on Vernex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vernex.

Explore the full profile